Hyperpigmentation after Foamed Bleomycin Sclerotherapy for Vascular Malformations

Heather C. Milbar; Hana Jeon; Margaret A. Ward; Sally E. Mitchell; Clifford R. Weiss; Bernard A. Cohen

doi:10.1016/j.jvir.2018.10.007

Hyperpigmentation after Foamed Bleomycin Sclerotherapy for Vascular Malformations

Heather C. Milbar, Hana Jeon, Margaret A. Ward, Sally E. Mitchell, Clifford R. Weiss, Bernard A. Cohen

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The present report documents 6 patients who developed distinctive hyperpigmented skin lesions after bleomycin sclerotherapy for vascular malformations of the face, neck, and extremities. The patients ranged in age from 2 to 65 years and included both black and white and male and female patients. The bleomycin treatment dose varied from 15 to 45 U, with 5 of the 6 patients receiving foamed bleomycin. The hyperpigmented lesions were near the patient's vascular anomaly and attributable to postprocedural cutaneous pressure (eg, electrocardiographic [ECG] leads or tape). Hyperpigmentation faded slowly over time but was visible up to 3 years after the procedure.

Original language	English (US)
Pages (from-to)	1438-1442
Number of pages	5
Journal	Journal of Vascular and Interventional Radiology
Volume	30
Issue number	9
DOIs	https://doi.org/10.1016/j.jvir.2018.10.007
State	Published - Sep 2019

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jvir.2018.10.007

Cite this

@article{2500f0e38ac049fa83d13089516a07ba,

title = "Hyperpigmentation after Foamed Bleomycin Sclerotherapy for Vascular Malformations",

abstract = "The present report documents 6 patients who developed distinctive hyperpigmented skin lesions after bleomycin sclerotherapy for vascular malformations of the face, neck, and extremities. The patients ranged in age from 2 to 65 years and included both black and white and male and female patients. The bleomycin treatment dose varied from 15 to 45 U, with 5 of the 6 patients receiving foamed bleomycin. The hyperpigmented lesions were near the patient's vascular anomaly and attributable to postprocedural cutaneous pressure (eg, electrocardiographic [ECG] leads or tape). Hyperpigmentation faded slowly over time but was visible up to 3 years after the procedure.",

author = "Milbar, {Heather C.} and Hana Jeon and Ward, {Margaret A.} and Mitchell, {Sally E.} and Weiss, {Clifford R.} and Cohen, {Bernard A.}",

note = "Publisher Copyright: {\textcopyright} 2018 SIR",

year = "2019",

month = sep,

doi = "10.1016/j.jvir.2018.10.007",

language = "English (US)",

volume = "30",

pages = "1438--1442",

journal = "Journal of Vascular and Interventional Radiology",

issn = "1051-0443",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Hyperpigmentation after Foamed Bleomycin Sclerotherapy for Vascular Malformations

AU - Milbar, Heather C.

AU - Jeon, Hana

AU - Ward, Margaret A.

AU - Mitchell, Sally E.

AU - Weiss, Clifford R.

AU - Cohen, Bernard A.

PY - 2019/9

Y1 - 2019/9

N2 - The present report documents 6 patients who developed distinctive hyperpigmented skin lesions after bleomycin sclerotherapy for vascular malformations of the face, neck, and extremities. The patients ranged in age from 2 to 65 years and included both black and white and male and female patients. The bleomycin treatment dose varied from 15 to 45 U, with 5 of the 6 patients receiving foamed bleomycin. The hyperpigmented lesions were near the patient's vascular anomaly and attributable to postprocedural cutaneous pressure (eg, electrocardiographic [ECG] leads or tape). Hyperpigmentation faded slowly over time but was visible up to 3 years after the procedure.

AB - The present report documents 6 patients who developed distinctive hyperpigmented skin lesions after bleomycin sclerotherapy for vascular malformations of the face, neck, and extremities. The patients ranged in age from 2 to 65 years and included both black and white and male and female patients. The bleomycin treatment dose varied from 15 to 45 U, with 5 of the 6 patients receiving foamed bleomycin. The hyperpigmented lesions were near the patient's vascular anomaly and attributable to postprocedural cutaneous pressure (eg, electrocardiographic [ECG] leads or tape). Hyperpigmentation faded slowly over time but was visible up to 3 years after the procedure.

UR - http://www.scopus.com/inward/record.url?scp=85063761796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063761796&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2018.10.007

DO - 10.1016/j.jvir.2018.10.007

M3 - Article

C2 - 30956080

AN - SCOPUS:85063761796

SN - 1051-0443

VL - 30

SP - 1438

EP - 1442

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

IS - 9

ER -

Hyperpigmentation after Foamed Bleomycin Sclerotherapy for Vascular Malformations

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this